Canopy Growth faces 1 make-or-break catalyst as DEA decision nears

The Drug Enforcement Administration's decision on whether to reclassify marijuana to Schedule III represents the defining catalyst for Canopy Growth (NASDAQ: CGC), with administrative hearings concluded and a ruling potentially weeks away.

"The rescheduling decision would remove the 280E tax burden for U.S. cannabis operators, fundamentally changing the economics of the industry," said James Okafor, macro analyst at Edgen. "For Canopy, it also opens the door to consolidating its U.S. affiliate without the current tax penalty."

The DEA's administrative hearing on rescheduling concluded in recent weeks after testimony from scientific witnesses, including the agency's own Dr. Akinfiresoye, who acknowledged that diversion from state medical marijuana programs had not been analyzed in the 2023 Department of Health and Human Services scientific review underpinning the recommendation. President Donald Trump's December executive order called for reclassification "in the most expeditious manner possible," though legal challenges — including an appeal from MMJ International Holdings before the D.C. Circuit — could complicate the timeline.

At stake for Canopy Growth is access to the U.S. market without the punitive tax treatment imposed by Section 280E of the Internal Revenue Code, which prevents cannabis companies from deducting ordinary business expenses. The company's Canopy USA subsidiary would benefit directly from a Schedule III classification, potentially unlocking significant tax savings and paving the way for full consolidation into the parent company. Legal experts remain confident the hearings will produce a favorable outcome, but the exact timing of a final DEA ruling remains uncertain.

Why the wait-and-see approach has merit

Canopy Growth shares have a history of rallying on rescheduling headlines only to retreat when details emerge. In April, following the last round of DEA-related legalization news, the stock surged alongside peers before giving back those gains. The pattern reflects a market that prices in the binary outcome of rescheduling without fully accounting for the implementation timeline or the procedural hurdles that remain.

The D.C. Circuit appeal filed by MMJ International Holdings — the only federally compliant cannabis drug developer with FDA Investigational New Drug authorizations — challenges the Attorney General's April 2026 Rescheduling Order on multiple grounds, including whether the Controlled Substances Act required formal rulemaking. MMJ CEO Duane Boise said the company was excluded from the DEA hearing despite having invested more than $10 million pursuing FDA approval for cannabinoid therapeutics targeting Huntington's disease and multiple sclerosis.

What rescheduling would unlock

A Schedule III classification would remove the 280E tax restriction, which currently forces U.S. cannabis operators to pay effective tax rates exceeding 70% in some cases. For Canopy Growth, the change would also facilitate the integration of Canopy USA, which holds interests in U.S. cannabis assets through its acquisitions of Acreage Holdings, Wana Brands, and Jetty Extracts.

The broader U.S. cannabis sector would benefit from improved access to banking services and potential uplisting to major exchanges, removing the overhang that has kept institutional capital on the sidelines. The last time the DEA signaled progress on rescheduling in April, the AdvisorShares Pure US Cannabis ETF (MSOS) surged more than 20% in a single session before paring gains.

For investors considering Canopy Growth, the calculus comes down to timing. Buying ahead of the decision risks a repeat of the April pattern — a headline-driven spike followed by a retreat as the market digests the details. Waiting for the ruling to arrive removes that binary risk, though it also means potentially missing the initial move. The long-term thesis hinges on federal legalization, not a single regulatory milestone.

This article is for informational purposes only and does not constitute investment advice.